Pediatrics Doctors in Columbus, MS Accepting Medicare

7 Pediatrics doctors found. Showing 1 - 7

Dr. Andrea Nicole Morris, MD Pediatrics Medicare: Accepting Medicare Assignments Practice Location: 2600 Fifth Street North, Columbus, MS 39705 Phone: 662-244-2960    Fax: 662-244-2964

Dr. Walter D Campbell, MD, MS Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 114 N Lehmberg Rd, Columbus, MS 39702 Phone: 662-329-2955    Fax: 662-370-1236

Pamela O Sykes, M.D. Pediatrics Medicare: Accepting Medicare Assignments Practice Location: 2402 5th Street North, Columbus, MS 39705 Phone: 662-327-8410    Fax: 662-327-9749

Marion Stewart, FNP-C Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 114 N Lehmberg Rd, Columbus, MS 39702 Phone: 662-329-2955    Fax: 662-370-1236

Dr. Jacob Skiwski, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 114 N Lehmberg Rd, Columbus, MS 39702 Phone: 662-329-2955    Fax: 662-328-6007

Christina D Collins, MD Pediatrics Medicare: Accepting Medicare Assignments Practice Location: 2600 Fifth Street, North, Columbus, MS 39705 Phone: 662-244-2960    Fax: 662-244-2917

Sara Kain, NP Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 114 N Lehmberg Rd, Columbus, MS 39702 Phone: 662-329-2955    Fax: 662-370-1236

News Archive

New evidence supports possible link between XMRV and prostate cancer

Xenotropic murine leukemia virus-related virus (XMRV) has been the subject of many studies since its discovery in 2006, but conflicting reports have created an unclear picture of XMRV's role in human disease. In three recent studies published in the November 15 issue of The Journal of Infectious Diseases, now available online, the evidence supports a possible link between XMRV and prostate cancer but not other links involving chronic fatigue syndrome, HIV infection, or hepatitis C virus (HCV) infection.

Preliminary results from Edison's EPI-A0001 28-day phase 2A trial against Friedreich's ataxia

Edison Pharmaceuticals, Inc. announced today preliminary results obtained on a 28-day phase 2A clinical trial in Friedreich's ataxia. While the primary endpoint of glucose disposition index did not show statistically significant improvement, EPI-A0001 did significantly improve neurological function as assessed by the Friedreich's Ataxia Rating Scale.

Genentech announces positive results from Phase II study of T-DM1

Genentech, Inc., a wholly owned member of the Roche Group, today announced positive results from a Phase II study of trastuzumab-DM1 (T-DM1). As assessed by independent review, T-DM1 shrank the tumors (also known as objective response) in 33 percent of women with advanced (metastatic) HER2-positive breast cancer that had worsened following previous treatment.

FDA warns public about extortion scam

The U.S. Food and Drug Administration is warning the public about criminals posing as FDA special agents and other law enforcement personnel as part of a continued international extortion scam.

Transcatheter Technologies implants transapical aortic valve in acute porcine model

Transcatheter Technologies GmbH (TT), an innovative medical device company that is developing a second-generation transcatheter aortic valve prosthesis, announced today that its proprietary transapical aortic valve has been successfully implanted in the acute porcine model.

Read more Medical News

› Verified 2 days ago